Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 2 (February)

1. Drug-Induced Pneumonitis Associated with Imatinib Mesylate in a Patient with Idiopathic Pulmonary Fibrosis.
   Respiration. [Abstract] [Full-text]
2. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
   Jpn J Clin Oncol, 36(1): 17-24. [Abstract] [Full-text]
3. Overcoming drug resistance in chronic myeloid leukemia.
   Curr Opin Hematol, 13(2): 79-86. [Abstract] [Full-text]
4. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
   Blood, 107(4): 1555-63. [Abstract] [Full-text]
5. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
   Blood, 107(4): 1591-8. [Abstract] [Full-text]
6. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia.
   Blood, 107(4): 1582-90. [Abstract] [Full-text]
7. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
   Am J Clin Oncol, 29(1): 12-3. [Abstract] [Full-text]
8. The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor.
   BJU Int, 97(3): 612-6. [Abstract] [Full-text]
9. Gene expression changes associated with progression and response in chronic myeloid leukemia.
   Proc Natl Acad Sci U S A. [Abstract] [Full-text]
10. Changing paradigms--an update on the multidisciplinary management of malignant glioma.
    Oncologist, 11(2): 165-80. [Abstract] [Full-text]
11. Synergistic suppression of rat neointimal hyperplasia by rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis.
    J Vasc Res, 43(2): 184-92. [Abstract] [Full-text]
12. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
    Oncogene, 25(7): 1118-24. [Abstract] [Full-text]
13. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
    Hypertension, 47(3): 467-74. [Abstract] [Full-text]
14. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
    Leuk Res, 30(4): 373-8. [Abstract] [Full-text]
15. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
    Blood, 107(5): 1791-9. [Abstract] [Full-text]
16. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
    Leukemia, 20(3): 400-3. [Abstract] [Full-text]
17. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
    Cancer, 106(5): 1188-96. [Abstract] [Full-text]
18. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
    Bone Marrow Transplant, 37(5): 439-49. [Abstract] [Full-text]
19. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Carcinogenesis, 27(3): 664-71. [Abstract] [Full-text]
20. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Ann Oncol, 17(3): 495-502. [Abstract] [Full-text]
21. Imatinib mesylate as a cause of acute liver failure.
    Am J Hematol, 81(3): 189-92. [Abstract] [Full-text]
22. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Gynecol Oncol, 101(1): 126-31. [Abstract] [Full-text]
23. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    J Clin Oncol, 24(7): 1204-8. [Abstract] [Full-text]
24. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    J Surg Oncol, 93(4): 304-11. [Abstract] [Full-text]
25. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    J Clin Oncol, 24(7): 1195-203. [Abstract] [Full-text]
26. Molecular targeted therapy: a strategy of disillusions or optimism?
    J Lab Clin Med, 147(3): 108-13. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.